Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHP611 intrathecal enzyme replacement study in late-infantile metachromatic leukodystrophy
MOH_2019-04-23_007097Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Apr 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cebsulfase alfa in metachromatic leukodystrophy (MLD), sponsored by Takeda. Started Apr 2019; status: recruiting.
02
Drugs
cebsulfase alfa
03
Conditions
metachromatic leukodystrophy (MLD)
Beyond the preview
Go deeper on MOH_2019-04-23_007097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-23_007097.